Intravitreal autologous XXXX prepared by urokinase for vitreolysis: a pilot study.

@entity1 @entity989 @entity548 @entity1596 @entity1351 @entity20699 @entity1020 @entity3225
PURPOSE: To evaluate the effects of intravitreal autologous @entity1351 injection (IVAP) on @entity989 and vitreolysis. METHODS: In this interventional, prospective, case series pilot study, 8 eyes were assigned to IVAP. Plasminogen as centrifuged from the @entity1 ' plasma was converted to @entity1351 by adding urokinase. A total of 0.2 mL extracted @entity1351 was injected intravitreally. @entity20699 ( @entity20699 ) and potential injection-related complications at week 4 were the primary outcome measures. Secondary outcomes included changes in best-corrected visual acuity (VA) (logMAR) and @entity1020 ( @entity1020 ). RESULTS: Mean age of the @entity1 was 54.35 years. Two @entity1 had complete @entity20699 and 3 @entity1 had partial @entity20699 . Four @entity1 had decrease in @entity1020 . The VA was not changed in 6 @entity1 , improved in 1 @entity1 , and decreased in 1 @entity1 . No @entity1596 , @entity3225 , or postinjection vitreous @entity548 was observed. CONCLUSIONS: This pilot study demonstrated the efficacy of urokinase-prepared IVAP injection on releasing vitreomacular traction and inducing vitreolysis.
